Revolution Medicines, Inc. Common Stock
RVMD
$147.90
+6.04%
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers, a historically difficult-to-treat genetic driver. The company is a recognized leader in the field, distinguished by its proprietary platform and chemical biology expertise to create small molecules that directly inhibit active RAS variants, known as RAS(ON) Inhibitors. The current investor narrative is overwhelmingly driven by the recent, highly positive Phase 3 data for its lead candidate, daraxonrasib, in pancreatic cancer, which demonstrated a doubling of survival versus chemotherapy, and the subsequent $2.2 billion capital raise to fund its ambitious late-stage development plans, positioning the company for a potential commercial launch.…
RVMD
Revolution Medicines, Inc. Common Stock
$147.90
Related headlines
RVMD 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Revolution Medicines, Inc. Common Stock's 12-month outlook, with a consensus price target around $192.27 and implied upside of +30.0% versus the current price.
Average Target
$192.27
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$118 - $192
Analyst target range
Analyst coverage appears robust and uniformly bullish, as evidenced by ten recent institutional ratings from major firms like Wells Fargo, JP Morgan, and RBC Capital, all reiterating Buy, Overweight, or Outperform ratings in January and February 2026 following key data releases. The provided data shows 6 analysts contributing to estimates, with a consensus estimated revenue average of $4.65 billion, though the range is extremely wide from $933.6 million to $14.54 billion, reflecting high uncertainty around the timing and magnitude of future sales. A formal consensus price target is not provided in the dataset, but the sustained bullish ratings from numerous top-tier firms in early 2026, coupled with the stock's subsequent ~40% rally in April, imply that analyst sentiment was positively aligned with the stock's upward move. The wide dispersion in revenue estimates underscores the binary nature of the investment—the high target assumes blockbuster adoption and success in multiple indications, while the low target may model more conservative penetration or development setbacks.
Bulls vs Bears: RVMD Investment Factors
The bull case, driven by transformative clinical data and a fortified balance sheet, currently holds stronger evidence, as reflected in the unanimous analyst bullishness and powerful technical breakout. However, the bear case presents a formidable counterpoint centered on extreme valuation and binary execution risk. The single most important tension in the investment debate is whether the current $15.1 billion market cap appropriately discounts the blockbuster potential of daraxonrasib ($14.5B high revenue estimate) or represents an unsustainable speculative bubble ahead of years of costly development and uncertain commercialization. The resolution hinges entirely on the drug's regulatory approval, launch execution, and ultimate market share.
Bullish
- Phase 3 Data Doubles Survival: Lead candidate daraxonrasib demonstrated a doubling of survival versus chemotherapy in pancreatic cancer, a breakthrough that could redefine the standard of care. This pivotal data is the primary driver behind the stock's 243% 1-year gain and validates the company's scientific platform.
- $2.2B Capital Raise De-risks Path: The recent $2.2 billion public offering provides a massive war chest to fund late-stage development and commercialization without near-term dilution risk. This transforms the balance sheet, evidenced by a strong current ratio of 7.14 and minimal debt-to-equity of 0.097.
- Unanimous Analyst Bullishness: Ten major institutional firms, including Wells Fargo and JP Morgan, issued Buy/Overweight ratings in early 2026 following the data release. This consensus reflects high conviction in the clinical and commercial potential, providing a strong sentiment floor for the stock.
- Massive Revenue Upside Potential: Analyst revenue estimates for daraxonrasib show a wide but high ceiling, with the high target at $14.54 billion, indicating blockbuster potential. The average estimate of $4.65 billion, while uncertain, underpins the current $15.1 billion market cap.
Bearish
- Pre-Revenue with Deep Losses: The company has no product revenue and is burning significant cash, with a TTM free cash flow of -$913.7 million and a Q4 2025 net loss of -$364.9 million. This makes the investment entirely binary on future clinical and regulatory success.
- Valuation Unmoored from Fundamentals: Traditional valuation metrics are inapplicable (PS=0, PE trailing=-13.4), making the $15.1 billion market cap a pure speculation on future sales. The stock trades at 90% of its 52-week high after a 243% run, indicating extreme optimism is already priced in.
- High Short Interest Signals Skepticism: A short ratio of 4.25 indicates a significant portion of the float is sold short, reflecting market skepticism about the sustainability of the rally or the long-term commercial outcome. This creates potential for sharp downside on any negative news.
- Revenue Estimates Show Extreme Uncertainty: Analyst revenue forecasts range wildly from $933.6 million to $14.54 billion, highlighting the binary risk and lack of visibility into future sales. The low-end estimate suggests a scenario where commercial adoption is far more modest than bulls expect.
RVMD Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 1-year price change of +243.21%, massively outperforming the SPY's +29.04%. As of the latest close at $139.48, the price is trading near the top of its 52-week range, approximately 90% of the way from the 52-week low of $34.0 to the high of $155.7, indicating strong momentum but also potential overextension after the recent parabolic move. Recent momentum is exceptionally strong but volatile; the stock surged +41.40% over the past month, far outpacing the SPY's +9.98%, though this follows a sharp pullback from the January peak near $123, with the 3-month change still a robust +43.87%. The price action shows a clear breakout from a consolidation range between $92 and $102 in early April, following the pivotal clinical data release, on explosive volume. Key technical support is now established in the $92-$96 zone, which was the pre-breakout consolidation base and aligns with the 52-week low of $34.0 being a distant floor. Immediate resistance is at the 52-week high of $155.7; a decisive breakout above this level could signal a continuation of the uptrend, while a failure could lead to a test of the $130-$135 support area. The stock's beta of 1.01 suggests its volatility is now roughly in line with the broader market, a notable shift given its biotech nature, potentially reflecting its transition to a later-stage, de-risked asset.
Beta
1.41
1.41x market volatility
Max Drawdown
-24.9%
Largest decline past year
52-Week Range
$34-$156
Price range past year
Annual Return
+263.2%
Cumulative gain past year
| Period | RVMD Return | S&P 500 |
|---|---|---|
| 1m | +49.2% | +9.5% |
| 3m | +54.1% | +4.1% |
| 6m | +149.2% | +6.0% |
| 1y | +263.2% | +26.7% |
| ytd | +87.2% | +5.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RVMD Fundamental Analysis
The company is a pre-revenue clinical-stage biotech, with quarterly revenue of $0 and a trailing twelve-month free cash flow of -$913.7 million, reflecting its intense investment in research and development. The revenue trajectory is non-existent currently, with the only income being a minor $7.0 million in collaboration revenue, but the investment thesis is entirely predicated on future revenue from its pipeline, most notably daraxonrasib. Profitability is deeply negative, with a Q4 2025 net income of -$364.9 million and an EPS of -$1.90, consistent with its clinical-stage status; however, losses have been widening sequentially as R&D expenses ramp for late-stage trials, with Q4 R&D of $292.6 million up from $188.1 million in Q4 2024. Gross margin data is not meaningful (0 or negative) as the company has no product sales, and all costs are expensed as R&D or SG&A. The balance sheet was recently transformed by the $2.2 billion public offering in April 2026, which followed a period of significant cash burn; prior to this, operating cash flow was -$274.2 million in Q4 2025. The current ratio is a very healthy 7.14, and the debt-to-equity ratio is a minimal 0.097, indicating a strong, equity-financed liquidity position post-offering that de-risks the path to potential commercialization, though Return on Equity (ROE) remains deeply negative at -69.35% due to the high net losses.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-913731000.0B
Last 12 Months
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RVMD Overvalued?
Given the company's negative net income and EBITDA, the primary valuation metric is the Price-to-Sales (PS) ratio. However, the PS ratio is reported as 0 due to negligible current revenue, making traditional multiples inapplicable; therefore, valuation is entirely forward-looking based on the potential of its clinical pipeline, particularly daraxonrasib. In the absence of a meaningful current PS or PE, peer comparison to industry averages is not feasible with the provided data; the stock's $15.1 billion market cap reflects a high-risk, high-reward bet on the future commercial success of its lead asset, with the recent capital raise validating institutional belief in that potential. Historically, the stock's own valuation has been in a state of extreme flux, with its price and market cap soaring on clinical catalysts; the current price near 52-week highs suggests the market is pricing in a high probability of success and future revenue streams, a significant re-rating from its earlier pre-data valuation levels.
PE
-13.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -22x~-6x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and inherent to the clinical-stage model. The company is pre-revenue, burning cash at an accelerating rate, with quarterly net losses widening to -$364.9 million in Q4 2025. While the $2.2 billion raise provides a multi-year runway, the path to profitability is long and uncertain, dependent on a single asset, daraxonrasib. The negative ROE of -69.35% and deeply negative free cash flow underscore that the business is entirely in investment mode, with no margin of safety if development stumbles.
Market & Competitive Risks center on valuation compression and clinical competition. Trading near its 52-week high after a 243% rally, the stock is priced for near-perfect execution. Any clinical setback, regulatory delay, or competitive advancement in the RAS oncology space could trigger a severe de-rating. The beta of 1.01 suggests its volatility is now aligned with the market, but this is a recent phenomenon; the stock's history and biotech nature imply it remains highly sensitive to sector-specific sentiment and risk-off moves in growth stocks.
Worst-Case Scenario involves daraxonrasib failing in subsequent trials, facing regulatory rejection, or being outcompeted by a rival therapy. In this scenario, the $15.1 billion market cap, built entirely on future daraxonrasib sales, would collapse. A realistic downside could see the stock re-testing its pre-data valuation levels around the $92-$96 technical support zone, representing a -31% to -34% decline from $139.48. A more severe bear case, factoring in a complete pipeline failure, could see a return toward the 52-week low of $34.0, a catastrophic -76% loss, though the strengthened balance sheet makes this less likely in the near term.